Collectively, these findings define a CDK1-KAT8 signaling axis that promotes NSCLC proliferation through epigenetic regulation and suggest that targeting CDK1-dependent KAT8 phosphorylation may represent a potential therapeutic strategy for lung cancer. Here, CDK1 is linked to lung carcinoma.